The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
- PMID:18410447
- DOI: 10.1111/j.1365-2141.2008.07147.x
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
Abstract
Relapsed/refractory myeloma has a poor outcome because of multi-drug resistance, patient low-performance status and toxicity of conventional chemotherapy. To improve results, standard chemotherapeutics and drugs targeting the microenvironment are applied at the same time. Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug-resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy-related toxicity, liposomal doxorubicin was added to a bortezomib-based combination. From January 2004, relapsed/refractory myeloma patients referred to our Institution received bortezomib 1.0 mg/m(2) i.v. twice weekly for 2 weeks in a 28-d cycle for up to six cycles, oral dexamethasone 24 mg with the standard scheduling and thalidomide 100 mg continuously (VTD). From January 2005, liposomal doxorubicin, 50 mg/m(2) (30 mg/m(2) for patients older than 75 years), was added on day 4 of each cycle [VTD plus Myocet (MyVTD)]. In total, 70 patients were treated: 28 received VTD and 42 MyVTD. Baseline demographic and clinical characteristics were similar between the two groups. Toxicity was manageable although more pronounced with MyVTD. The overall response rate (81% vs. 50%, P = 0.009), time to progression (19 vs. 11 months, P = 0.01) and progression-free survival (15 vs. 8 months, P = 0.001) were significantly higher with MyVTD regimen, suggesting an improved quality of response.
Similar articles
- Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.Offidani M, et al.Eur J Haematol. 2007 Apr;78(4):297-302. doi: 10.1111/j.1600-0609.2007.00823.x. Epub 2007 Feb 5.Eur J Haematol. 2007.PMID:17286608
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.Orlowski RZ, et al.J Clin Oncol. 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6.J Clin Oncol. 2007.PMID:17679727Clinical Trial.
- Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.Lee SS, et al.Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.Ann Hematol. 2010.PMID:20349060Clinical Trial.
- Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.Badros A, et al.Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921.Cancer. 2007.PMID:17654660Review.
- Management of multiple myeloma with bortezomib: experts review the data and debate the issues.Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.Dicato M, et al.Oncology. 2006;70(6):474-82. doi: 10.1159/000099284. Epub 2007 Feb 2.Oncology. 2006.PMID:17283449Review.
Cited by
- Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).Wiernik PH.Wiernik PH.Curr Treat Options Oncol. 2009 Apr;10(1-2):1-15. doi: 10.1007/s11864-008-0077-x. Epub 2008 Nov 19.Curr Treat Options Oncol. 2009.PMID:19016330Review.
- A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.Liu J, Zheng H, Tang M, Ryu YC, Wang X.Liu J, et al.Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2541-50. doi: 10.1152/ajpheart.01052.2008. Epub 2008 Oct 31.Am J Physiol Heart Circ Physiol. 2008.PMID:18978187Free PMC article.
- The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Rehman W, Arfons LM, Lazarus HM.Rehman W, et al.Ther Adv Hematol. 2011 Oct;2(5):291-308. doi: 10.1177/2040620711413165.Ther Adv Hematol. 2011.PMID:23556097Free PMC article.
- Advances in treatment for relapses and refractory multiple myeloma.Richards T, Weber D.Richards T, et al.Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6.Med Oncol. 2010.PMID:20213220Review.
- Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P.Broijl A, et al.Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.Haematologica. 2016.PMID:26659914Free PMC article.Clinical Trial.No abstract available.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical